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Background: Serum proteins that non-specifically bind 
with human S100A8/A9 (h-S100A8/A9) have been 
proposed.  Our aim was to isolate and identify these 
proteins, and verify their clinical significance for 
monitoring the postoperative condition of liver recipients, 
and further to discuss the transportation of human 
fibronectin (h-FN) with h-S100A8/A9 and its functional 
role in vivo. 
Methods: To isolate the serum proteins, recombinant 
human S100A8, S100A9 and S100A8/A9 affinity 
columns were used.  Proteins were identified by mass 
spectrometry.  Two enzyme-linked immunosorbent 
assays (ELISA) were used to measure h-S100A8/A9 and 
h-FN in the sera of liver recipients.  Flow cytometry 
was employed to detect h-S100A8/A9 and h-FN on 
immunological cells.  Western blotting was used to 
confirm serum constituents using antibodies specific to 
each constituent. 
Results: One of the proteins was identified with h-FN, 
and its fluctuation pattern in the serum of the recipient 
was in contrast to that of CRP.  Flow cytometry showed 
a positive reaction for h-S100A8/A9 and h-FN on 
neutrophils and monocytes, indicating that both proteins 
exist on these cells. 
Conclusions: The h-FN could be transported with 
S100A8/A9 in blood and/or on immunological cells, and 
effectively prevent further attack by various internal 
oxidants or repair damaged liver tissue in vivo. 
 
Keywords: S100 proteins; fibronectin; inflammation; 
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1. Introduction 
 Human S100 proteins, h-S100A8, h-S100A9 and 
h-S100A8/A9, were first found in the synovial fluid of 
patients with rheumatoid arthritis [1].  S100 proteins are 
characterized by their origin and immunological 
properties in activated neutrophils and/or macrophages 
[2-6].  To date, a variety of their immunological 
functions in inflammation have been subjected to 
investigation by many researchers.  Although S100 
proteins are reportedly involved in the induction of acute 
inflammation, their immunological properties have not 
necessarily been clarified, which is of note [7-11].  We 
recently reported that among S100 proteins, 
h-S100A8/A9 was markedly increased in the serum of a 
recipient of small intestine transplantation with acute 
inflammation associated with rejection [12].  In this 
case, fluctuation of the serum level of S100A8/A9 did 
not correspond to that of C-reactive protein (CRP), 
indicating that the functional role of h-S100A8/A9 is 
different from that of CRP.  h-S100A8/A9 binds with 
heparin, heparin sulfate glycosaminoglycans on 
endothelial cells, and arachidonic acid with high affinity, 
indicating a potential property that is essentially different 
from that of CRP [13,14].  Against such a background, 
we hypothesized the existence of other constituents 
binding with h-S100A8/A9 in the human serum.  In this 
study, we describe another potential property of 
h-S100A8/9 and its interaction with serum constituents, 
and present data supporting its functional role. 
 
2. Materials and methods 
2.1. Materials 
 SephacrylTM S-300 HR was purchased from 
Parmacia Co. Ltd., Uppsala, Sweden; human serum 
fibronectin (h-FN) was obtained from BD Biosciences 
Co. Ltd., San Jose, CA; fluorescein 5-isothiocyanate 
(FITC) and lipopolysacchride (LPS) were from Sigma 
Chemical, Co. Ltd., St. Louis, MO; streptavidin 
(STA)-horseradish peroxidase (HRP), STA-Texas Red 
and anti-rabbit IgG (goat) IgG-HRP conjugates, and 
biotin (Long arm)-NHS were obtained from Vector Co. 
Ltd., Burlingame, CA; all others were from Nacalai 
Tesque or Wakenyaku Co. Ltd., Kyoto, Japan. 
 
2.2. Methods 





2.2.1. Expression of cDNA for h-S100A8 or h-S100A9 
 cDNAs with histidine tag sequences for h-S100A8 
and h-S100A9 were synthesized using common gene 
technology, including polymerase chain reaction (PCR).  
The two cDNAs were each inserted into a pCold-I vector 
(Takara Bio Co. Ltd., Kyoto, Japan) [15].  The two 
vectors were transformed into E. coli cells (BL21), 
respectively.  The recombinant cells were cultivated in 
a large culture bottle (approx. 8 liters of LB broth) at 37 
˚C for 12 h.  When the absorbance of the culture 
medium at 600 nm reached 0.5 to 0.8, the temperature in 
the bottle was quickly reduced to 15 ˚C.  E. coli cells 
were further cultivated for 24 h at the same temperature 
after adding 1 mmol/l 
isopropyl-β-D(-)-thiogalactopyranoside as the final 
concentration.  The cells were harvested and washed 
once with 50 mmol/l Tri-HCl buffer (pH7.4)/0.15 mol/l 
NaCl, and kept frozen at -80 ˚C until use. 
 
2.2.2. Purification of recombinant human S100A8 and 
S100A9 
 E. coli cells (approx. 5 g) expressing recombinant 
human S100A8 (r-S100A8) or S100A9 (r-S100A9) were 
re-suspended in 0.25 liters of 10 mmol/l imidazole/0.3 
mol/l NaCl/50 mmol/l phosphate buffer (pH8.0) for 1 h 
at room temperature, and then treated using an ultrasonic 
generator for 10 to 15 min at 4 ˚C.  After centrifugation 
at 18560×g for 20 min at 4 ˚C, clear supernatant was 
applied to an Ni-agarose affinity column (19×50 mm) 
equilibrated with the same buffer solution.  After 
washing with 20 mmol/l imidazole/0.3 mol/l NaCl/50 
mmol/l phosphate buffer (pH8.0) thoroughly, r-S100A8 
or r-S100A9 was eluted from each column with 0.25 
mol/l imidazole/0.3 mol/l NaCl/50 mmol/l phosphate 
buffer (pH8.0).  Major fractions containing r-S100A8 
or r-S100A9 were collected and then dialyzed against 50 
mmol/l phosphate buffer (pH8.0)/0.3 mol/l NaCl at 4 ˚C 
overnight, and kept frozen at -80 ˚C until use.  The 
concentrations of the products were determined by the 
method of Lowry et al. using bovine serum albumin as a 
standard [16]. 
 
2.2.3. Preparation and purification of recombinant 
human S100A8/A9 
 r-S100A8 was mixed with r-S100A9 at a mole 
ratio of approximately one.  The mixture was placed in 
a dialysis tube followed by incubation in dialyzed against 
2.0 mol/l Tris-NaOH solution (pH12) at 4 ˚C overnight.  
Recombinant human S100A8/A9 (r-S100A8/A9) was 
purified through a gel filtration column embedded with 
SephacrylTM S-300 HR (25×1000 mm) and equilibrated 
with 50 mmol/l Tris-HCl buffer (pH10)/0.3 mol/l NaCl.  
Major fractions containing r-S100A8/A9 were collected 
and concentrated to an adequate volume, and kept frozen 
at -80 ˚C until use. 
 
2.2.4. SDS-PAGE and Western blotting 
 Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was carried out in the 
absence of 2-mercaptoethanol (2-ME) according to the 
method of Towbin et al. [17].  Proteins in the gel were 
electrophoretically transferred to a sheet of nitrocellulose 
membrane.  Western blotting was also carried out to 
confirm the cross-reactivity of anti-h-S100A8/A9 
antibody with r-S100A8/A9.  An antibody-bound 
protein band was finally visualized as described 
previously [12]. 
 
2.2.5. Isolation of serum proteins that bind with r-S100 
proteins from the sera of patients 
 Human pooled serum from many patients was 
preliminarily diluted about three-fold with 50 mmol/l 
phosphate buffer (pH7.2)/0.15 mol/l NaCl (buffer A).  
One hundred milliliters of the working pooled serum was 
applied to r-S100A8-, r-S100A9- and 
r-S100A8/A9-Sepharose 4B columns (19×50 mm), 
respectively.  After washing with buffer A, proteins 
were eluted from each column with 0.2 mol/l glycine 
buffer (pH2.3) and concentrated to an adequate volume.  
The proteins were dialyzed against 2 liters of buffer A at 
4 ˚C overnight and then kept frozen at -80 ˚C until use. 
 
2.2.6. Preparation of antibodies directed to serum 
proteins binding with r-S100 proteins 
 Antisera were raised in rabbits against serum 
proteins that bind with r-S100 proteins [12].  From the 
antiserum, partially purified IgG was obtained by 
precipitation with 60% saturated ammonium sulfate and 
DEAE-cellulose (DE52) chromatography.  Fractions 
containing IgG were collected and mixed with 7.7 
mmol/l sodium azide as the final concentration.  
Anti-h-FN IgG was affinity-purified using an 
h-FN-Sepharose 4B column [12]. 
 
2.2.7. Mass spectrometry 
 Mass spectrometric identification of proteins was 
performed as previously described [18]. Briefly, after 
SDS-PAGE, proteins were visualized by CBB staining 
and excised separately from gels, followed by in-gel 
digestion with trypsin (Promega Corporation) in 50 
mmol/l ammonium bicarbonate buffer (pH8.0) 
containing 2 % acetonitrile overnight at 37 ˚C. Molecular 
mass analyses of triptic peptides were performed by 
matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF/MS) using a ultraflex 
TOF/TOF (Bruker Daltonics). Proteins were identified 
by comparing the molecular weights determined by 
MALDI-TOF/MS and theoretical peptide masses from 
the proteins registered in NCBInr. 
 
2.2.8. Biotin and FITC labeling 
 Biotinylation of proteins with biotin 
(Long-arm)-NHS and FITC labeling was carried out 
according to the manufacturer’s instructions.  Unbound 
biotin-NHS was dialyzed for 12 h at 4 ˚C against 2 liters 
of buffer A.  The procedures were repeated twice, 
replacing the 2 liters of buffer A.  The labeled products 
were kept in a refrigerator until use.  Unbound FITC 
was removed through a Sephadex G-25 column (15×600 
mm) for gel filtration in the dark.  Major fractions 





containing FITC-labeled proteins were collected, 
concentrated and then kept in a refrigerator in the dark. 
 
2.2.9. Measurement of h-FN, h-S100A8/A9 and another 
laboratory markers 
 To measure h-FN in the sera of liver recipients, we 
newly developed an enzyme-linked immunosorbent 
assay (ELISA) for h-FN, as described previously [12].  
Except for immobilization of the primary antibody, all 
procedures were carried out at room temperature.  
Briefly, the procedures were as follows: 25 µl of serum 
sample (500-fold dilution with Blocking One; Nacalai 
Tesque Co. Ltd.) was added to each well of a 96-well 
polycarbonate plate, which was preliminarily coated with 
anti-h-FN (rabbit) IgG (5 mg/l in 75 mmol/l carbonate 
buffer, pH9.5), followed by incubation for 1 h to allow 
immunological reaction.  After washing, 100 µl of 
anti-h-FN (rabbit) IgG-biotin conjugate, diluted 
adequately with the standard matrix solution, was added 
to each well of the plate, followed by further incubation 
for 1 h.  The plate was washed again as above with the 
same washing solution, and 100 µl of STA-HRP 
conjugate was added to all wells of the plate, and further 
incubated for 30 min to form the biotin-STA-HRP 
complex.  Finally, HRP activity was determined 
colorimetrically.  h-S100A8/A9 was measured by 
ELISA.  For comparison, other serum markers, such as 
CRP, AST and ALT, were also determined using an 
automatic chemical analyzer. 
 
2.2.10. Flow cytometry 
 Sample preparation was carried out as follows: 
human leukocytes from many healthy volunteers were 
separated, as described previously [12], and 
re-suspended at about 5×106/ml in Hank’s Balanced Salt 
Solution (HBSS).  All cells were blocked with rabbit 
IgG from non-immunized rabbits (10 µg/ml as a final 
concentration) for 20 min on ice.  Some of the cells was 
used as a negative control, and residual cells were 
stained with anti-h-S100A8/A9 IgG-, anti-h-FN IgG-, 
and h-FN-FITC conjugates, respectively, for 30 min on 
ice.  h-FN-FITC conjugate was used to examine 
whether h-FN binds to immunological cells, such as 
neutrophils and monocytes.  All cells were finally 
re-suspended in an adequate volume of the same solution, 
and then analyzed by flow cytometry using 
FACSvantage (BD Biosciences Co. Ltd., Tokyo, Japan) 
equipped with CellQuest software. 
 
2.2.11. Possible existence of h-FN-h-S100A8/A9 complex 
 The existence of the h-FN-h-S100A8/A9 complex 
in the sera of liver recipients was examined using an 
anti-h-FN (rabbit) IgG-Sepharose 4B column, based on 
its immunological properties.  Briefly, pooled serum of 
the recipients, which was adequately diluted with buffer 
A, was applied to the column.  After washing with 
buffer A, proteins were eluted with 0.2 mol/l glycine 
buffer (pH2.3), and the pH of the solution was quickly 
adjusted to 7.0 with 2.0 mol/l NaOH.  To detect the 
h-FN-h-S100A8/A9 complex, ELISA for h-S100A8/A9, 
in which anti-h-S100A8/A9 monoclonal antibody 
(Mo2B9) was used as the first antibody, was employed 
[12].  Anti-h-FN IgG-biotin complex with STA-HRP 
was used to detect h-FN-h-S100A8/A9 complex as a 
second antibody.  In addition, anti-h-S100A8/A9 
Fab’-HRP conjugate was also used to determine free 
h-S100A8/A9 as a second antibody. 
 
2.2.12. Statistical analysis 
 Statistical analysis was performed using the 
parametric test for pair-wise comparisons with controls.  
Significant differences between groups were identified 
using Student’s t-test (for the difference between two 




3.1. Preparation of r-S100A8, r-S100A9 and 
r-S100A8/A9 
 Both r-S100A8 and r-S100A9 were successfully 
expressed in E. coli cells.  As shown in Figure 1, the 
purity of r-S100A8 and r-S100A9 together was ~95%, as 
determined visually (Fig. 1A, lanes a and b).  
Preparation of r-S100A8/A9 was also successfully 
achieved in vitro.  Crude r-S100A8/A9 was purified 
using a gel filtration column (see Methods).  When 
examined by SDS-PAGE, the purity was >95% visually 
(Fig. 1B, lane d). 
 
 
Fig. 1. Preparation and purification of r-S100A8, r-S100A9 
and r-S100A8/A9 
 SDS-PAGE was carried out in the presence (Fig. 1A) 
and absence (Fig. 1B) of 2-ME.  In A, lane M1 shows 
molecular mass markers.  Lanes a and b show purified 
r-S100A8 and r-S100A9, respectively.  In B, lanes M2 and M3 
show molecular mass markers.  Lanes c and d contain purified 
r-S100A8/A9 (main band), and r-S100A8 and S100A9 
monomers (minor bands).  Anti-h-S100A8/A9 (rabbit) IgG was 
used as the first antibody and anti-rabbit IgG (goat) IgG-HRP 
conjugate as the second antibody (lane c). 
 
3.2. Reactivity of anti-h-S100A8/A9 antibody with 
r-S100A8/A9 
 Anti-h-S100A8/A9 antibody apparently reacted 
with r-S100A8/A9, but not with r-S100A8 or r-S100A9 
monomer (Fig. 1B, lane c), indicating that the antibody 
could recognize the three-dimensional structure of 





r-S100A8/A9.  As a result, r-S100A8/A9 was 
practically equivalent to h-S100A8/A9 [12]. 
 
3.3. Identification by mass spectrometry 
 Serum proteins that bound with r-S100A8, 
r-S100A9 and r-S100A8/A9 were isolated from the sera 
of many patients using each affinity column (see 
Methods).  As examined by SDS-PAGE in the presence 
of 2-ME, various proteins were contained in the sample 
from each column (Fig. 2A, lanes a-c).  Interestingly, 
these proteins were eluted with 0.2 mol/l glycine buffer 
(pH2.3), but not with 9 mmol/l acetic acid, indicating 
that they bound tightly, to some extent, to r-S100A8, 
r-S100A9, and r-S100A8/A9 affinity columns.  As 
confirmed by Western blotting, antibodies directed to 
these serum proteins positively reacted with many 
protein bands (Fig. 2B, lanes a-c).  Among them, 
fourteen proteins, including their subunits, corresponding 
to the positive bands were identified by mass 
spectrometry (Fig. 3, p1~p14), one of which was serum 
fibronectin (Table 1).  Also of note, some 
coagulation-related factors were identified. 
 
 
Fig. 2. Isolation of serum constituents binding with 
r-S100A8/A9 from human sera of patients 
 In A, SDS-PAGE for serum constituents binding with 
r-S100A8/A9 was carried out in the presence of 2-ME.  Lane 
M shows molecular mass markers.  Lanes 1, 2 and 3 show 
protein bands of the serum constituents eluted from r-S100A8-, 
r-S100A9- and r-S100A8/A9-Sepharose 4B affinity columns, 
respectively.  In B, anti-serum constituents antibodies 
preliminary raised in rabbits and anti-rabbit IgG (goat) 
IgG-HRP were used as the first and second antibodies, 
respectively.  Loaded samples of lanes a, b and c in panel A 
correspond to those in panel B, respectively. 
 
Fig. 3. Protein bands of serum constituents identified by mass 
spectrometry 
 SDS-PAGE was carried out using polyacrylamide 
gels of 100 g/l, 125 g/l or 150 g/l in the presence of 2-ME.  
Proteins were stained with Coomassie brilliant blue R-250.  
Protein bands of the serum constituents (P1 to P14) were 
identified by mass spectrometry. 
 
Table 1 
Identification of PXs by mass spectrometry 
 
 Proteins identified 
 
P1 IgM chain C region 
P2 Serum albumin 
P3 Plasminogen 
P4 Plasminogen 
P5 Plasminogen and Fibrinogen beta chain 
P6 Plasminogen 
P7 Plasminogen and Fibulin-1 
P8 Serum albumin 
P9 IgM chain C region and Antithrombin-III 
P10 Fibronectin 
P11 Immunoglobulin light chain 
P12 Immunoglobulin light chain 
P13 Antithrombin-III／IGHA1a and 
 Inter-alpha-trypsin inhibitor heavy chain H4 
P14 Fibronectin 
 
a: Ig alpha-1 chain C region 
 
3.4. Interaction between h-FN and h-S100A8/A9 in vitro 
 It was examined whether h-S100A8/A9 binds to an 
h-FN-Sepharose 4B column.  As determined by ELISA 
for h-S100A8/A9, the reaction was apparently positive, 
indicating that h-S100A8/A9 exactly binds to the affinity 
column (Figs. 4A and 4B, lane E).  This strongly 
suggests that h-S100A8/A9 interacts with h-FN to form a 
complex in vivo. 
 
 
Fig. 4. Interaction between h-FN and h-S100A8/A9 in vitro 
 Examination of interaction between h-FN and 
h-S100A8/A9 in vitro was carried out using the 
h-FN-Sepharose 4B affinity column.  1.5 ml of h-S100A8/A9 
(approx. 1 mg) was applied to the column.  h-S100A8/A9 
bound to the column was eluted with 0.2 mol/l glycine buffer 
(pH2.3).  Panels A, B and C show SDS-PAGE, Western 
blotting and ELISA, respectively.  P and E in all panels 
indicate pass and elution fractions from the column, 
respectively.  Lane M shows molecular mass markers.  Panel 
C shows ELISA for h-S100A8/A9, in which S indicated 
h-S100A8/A9 before its application to the column.  P1~P7 
indicate pass fractions from the column.  W indicates a pass 
fraction of washing solution.  E1~E7 are eluates from the 
column. 
 





3.5. Possible h-FN-h-S100A8/A9 complex formation in 
serum 
 To measure free h-S100A8/A9 in the eluate, 
ELISA for h-S100A8/A9  was carried out (see 
Methods).  In ELISA, the reaction was apparently 
positive and linear for h-S100A8/A9 in proportion to the 
dilution ratio of the eluate (Fig. 5A).  Meanwhile, when 
anti-h-FN antibody-biotin-STA-HRP complex was used 
as the second antibody in ELISA, it also showed a 
positive reaction (Fig. 5B).  These data indicate that 
free S100A8/A9 and h-FN-h-S100A8/A9 complex exist 
together in the eluate due to the immunological 
properties of the antibodies used in this study. 
 
Fig. 5. Examination of h-FN-h-S100A8/A9 complexes by ELISA 
 To isolate h-FN-h-S100A8/A9 complex in the sera 
of liver recipients, an anti-h-FN IgG-Sepharose 4B column was 
used.  In A, free h-S100A8/A9 was determined by the ELISA 
previously described [13].  In B, anti-h-FN IgG-biotin 
conjugate, together with STA-HRP, was used as the second 
antibody to capture the h-FN component of the complex in the 
eluate.  In A and B, a two-fold dilution series of the eluate was 
used to detect the complex. 
 
3.6. Linearity and sensitivity of ELISA for h-FN, and its 
precision 
 We newly developed an ELISA for h-FN as 
described in Methods.  A novel standard curve was 
obtained using 2 mg/l h-FN standard (BD Biosciences 
Co. Ltd.) (Fig. 6A).  Under the standard conditions, the 
ELISA reaction was linear for h-FN from 0 to 930 µg/l 
(Fig. 6B).  We assessed the reproducibility of the 
method using purified h-FN and pooled sera from 
healthy individuals or patients with various liver diseases.  
Within-day CVs were in the range of 3.0% to 5.2%, and 
between-day CVs were between 5.5% and 11.2%, 
indicating the fairly good reproducibility of this ELISA.  
The recovery of endogenous plus exogenous h-FN was 
108% (mean), with a range of 96% to 120%.  The 
normal reference interval, as estimated by this method 
with sera obtained from 103 healthy individuals [48 men 
and 56 women; age 18-35 (mean 24) years], was 366 
mg/l ± 19.1 mg/l (mean ± 2SD). 
 
Fig. 6. Linearity and sensitivity of the ELISA for h-FN, and its 
precision and recovery 
 In A, h-FN (BD Biosciences Co. Ltd.) was used as 
the standard.  In B, two pooled sera with different 
concentrations (low and high) were used to confirm the 
linearity of the ELISA. 
 
3.7. Application of ELISA for h-FN to clinical samples 
 To assess the clinical value of our new ELISA for 
h-FN, we examined sera obtained from five liver 
recipients.  Among them, data from a representative 
recipient are presented in this study.  For comparison, 
the presence of other markers, such as h-S100A8/A9, 
CRP, AST and ALT, in serum were also determined. 
 The patient (a 63-year-old man), hospitalized with 
hepatocellular carcinoma, underwent liver 
transplantation from a living-related donor.  Prominent 
peaks for AST and ALT were seen immediately after the 
operation, accompanied with h-S100A8/A9 and CRP, 
but subsequently disappeared within one week (Fig. 7).  
The level of CRP began to markedly increase a little later, 
transiently maintained a high level in the serum, and then 
gradually decreased (horizontal bar).  Meanwhile, an 
increase in the h-S100A8/A9 level was seen little after 
that of CRP and soon peaked, gradually decreasing a 
month later.  The level of h-FN, however, began to 
decrease immediately after the operation and remained 
low until it increased about two weeks after surgery.  
Thus, the fluctuation pattern of the serum level of h-FN 
was almost in contrast to that of CRP. 
 
 
Fig. 7. Changes in h-FN, h-S100A8/A9, CRP and other 
laboratory markers in serum of a liver recipient 
 Liver transplantation was performed for hepacocellular 
carcinoma associated with liver cirrhosis (c-type).  
Concentrations of h-S100A8/A9 and h-FN were measured by 
the ELISA methods for each protein, respectively.  Other 
laboratory markers were measured using an automatic 
chemical analyzer (TBA200FR-Neo; TOSHIBA, Tokyo).  The 
day of surgery is indicated by a vertical open triangle.  Values 
are presented as the relative ratio to the upper value of the 
normal range of each marker. 
 
3.8. Observation of h-S100A8/A9 and h-FN on 
immunological cells 
 As examined by flow cytometry, the h-S100A8/A9 
reaction was apparently positive on neutrophils and 
monocytes, whereas that for h-FN was lower, indicating 
however that both h-S100A8/A9 and h-FN exist on these 
immunological cells (Fig. 8, panels N1 and M1).  On 
the other hand, no positive reaction for either protein was 
seen on lymphocytes (Fig. 8, panel L1).  In addition, 
h-FN bound to both neutrophils and monocytes, but not 





to lymphocytes (Fig. 8, panels N2, M2 and L2). 
 
 
Fig. 8. Detection of h-FN and h-S100A8/A9 on surface 
membrane of immunological cells 
 Panels N1 and N2 show neutrophils.  Panels M1 and 
M2 show monocytes.  Panels L1 and L2 show lymphocytes.  
In all panels, dotted line indicates negative control.  In panels 
N1, M1 and L1, heavy and thin solid lines indicate 
h-S100A8/A9 and h-FN, respectively.  In panels N2, M2 and 
L2, heavy and thin solid lines indicate h-FN and human 
albumin (internal control). 
 
4. Discussion 
 In this paper, we have described the isolation and 
identification of new serum constituents that 
non-specifically bind with r-S100A8-, r-S100A9- and 
r-S100A8/A9-Sepharose 4B columns.   In addition, we 
have mentioned the potential of h-S100A8/A9 as a 
carrier protein for serum constituents and presented data 
supporting its functional role.  h-S100A8/A9 is closely 
involved in acute inflammation because the production 
and secretion of h-S100A8/A9 is almost entirely limited 
to activated neutrophils and macrophages in acute 
inflammation [19].  Thus, the value of h-S100A8/A9 in 
vivo is based on its origin and immunological properties. 
 The property of h-FN to bind tightly, under some 
conditions, with an r-S100A8/A9 affinity column in vitro 
may be helpful for understanding its functional role in 
vivo.  The interaction of h-FN with h-S100A8/A9 is 
noteworthy because h-FN is reportedly a protein that 
binds with various constituents in vivo.  In the present 
study, we demonstrated the existence of h-S100A8/A9 
and h-FN on immunological cells, such as neutrophils 
and monocytes, or the adhesion of h-FN to both cells, as 
well as the interaction of h-S100A8/A9 and h-FN with 
high affinity in vitro (Figs. 4, 5 and 8).  These data 
strongly support our hypothesis that h-FN could be 
transported with h-S100A8/A9 in blood and/or on 
immunological cells.  Transported h-FN is consumed 
after partial hepatectomy to prevent further attack by 
various internal oxidants or to repair damaged tissues 
during and after surgery, although its mechanism 
remains unclear [20].  For elucidation, we focused on 
the postoperative fluctuation of h-FN levels in the sera of 
liver recipients, together with other laboratory markers.  
Interestingly, the fluctuation pattern was in contrast to 
that of the CRP level for a short period (Fig. 6, 
horizontal bar).  As described above, this probably 
reflects the possibility of h-FN being consumed to 
protect the liver graft after transplantation.  Thus, we 
found that h-FN is clinically another useful biomarker 
for monitoring the postoperative condition of liver 
recipients, and that h-S100A8/A9 could serve as its 
carrier protein in vivo in the acute inflammatory phase. 
 Comprehensive elucidation of the immunological 
properties of h-S100A8/A9 has long been desired, but it 
has not necessarily been achieved because of the 
complication of immune reactions in vivo; however it 
was reported that S-nitrosylated S100A8 is a protein with 
anti-inflammatory properties [21].  This supports our 
hypothesis concerning the functional role of 
h-S100A8/A9 in acute inflammation.  Recently, 
microscopic images showed the co-localization of 
h-S100A8/A9 and h-FN on immunological cells, and the 
accumulation of h-FN, which may be diffusely released 
from the cells, bound with damaged liver tissue (data not 
shown).  Integrin commonly exists on endothelial cells 
of capillary vessels and adheres to various serum 
constituents, functioning as a mediator on the cells 
[22,23].  h-FN transported to endothelial cells with 
h-S100A8/A9 and/or on immunological cells may be 
further translocated near to an inflamed area via such an 
integrin or these cells, although the mechanism remains 
unclear.  In the present study, we also mentioned a 
mechanism for understanding the effect of h-FN on 
suppression of the inflammatory reaction in damaged 
liver tissue. 
 On the other hand, it is noteworthy that several 
coagulation factors, such as antithrombin III, 
plasminogen and fibrinogen, were identified in this study 
(Table 1).  Thus, h-S100A8/A9 seems to be closely 
related to pathological conditions, such as the 
disseminated intravascular coagulation phenomenon 
(DIC) that probably occurs, to a greater or lesser extent, 
in the bloodstream after liver transplantation.  
Interaction between h-S100A8/A9 and these coagulant 
factors in vivo may show an influence on the DIC, which 
is of note.  Indeed, marked fluctuation of the level of 
antithrombin III, measured by ELISA, in the serum of a 
liver recipient was observed (data not shown).  If the 
DIC is in an advanced stage, the condition of a liver 
recipient may deteriorate postoperatively.  It is 
therefore clinically very important to reduce DIC as early 
as possible.  Recently, h-S100A8/A9-serum constituent 
complexes, isolated from the serum of patients using an 
anti-h-S100A8/A9 IgG-Sepharose 4B column, were 
clearly demonstrated by SDS-PAGE in the presence and 
absence of 2-ME (data not shown).  When antibodies 
directed to serum constituents that bind with r-S100 
proteins were used, Western blotting showed a positive 
reaction, indicating that coagulation factors were 
contained in these complexes.  This may enable the 
preparation of monoclonal antibodies against epitopes of 
the three-dimensional structure of 
h-S100A8/A9-coagulation factor complexes, and to 
develop an ELISA for these complexes.  Our current 
investigations are focusing on the preparation of such 
monoclonal antibodies specific to these complexes. 
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 h-FN, human fibronectin; LPS, lipopolysaccharide; 
FITC, fluorescein 5-isothiocyanate; SDS, sodium dodecyl 
sulfate; SDS-PAGE, polyacrylamide gel electrophoresis in the 
presence of SDS; 2-ME, 2-mercaptoethanol; STA, streptavidin; 
HRP, horseradish peroxidase; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; CRP, C-reactive protein; 
ELISA, enzyme-linked immunosorbent assay; DIC, 
disseminated intravascular coagulation. 
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